Although CAR T cell therapy has had impressive efficacy in targeting leukaemias and lymphomas expressing ubiquitous antigens such as CD19, the administration of amph-CAR ligands provides a strategy for the universal treatment of solid tumours where tumour antigen selection is more problematic, greatly expanding the patient population that might benefit from adoptive cell therapy. The gene discussed is CD19; the disease is lymphoma.